Previous close | 214.80 |
Open | 206.50 |
Bid | 215.40 x N/A |
Ask | 216.30 x N/A |
Day's range | 206.50 - 206.50 |
52-week range | 178.90 - 263.00 |
Volume | |
Avg. volume | 1 |
Market cap | N/A |
Beta (5Y monthly) | -0.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease. Eisai has also collaborated with a major Chinese medical insurance firm to plan partial coverage of the drug cost, the companies said without naming the insurer. China approved the treatment in January after a standard approval from the U.S. Food and Drug Administration last July.
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
Investors need to pay close attention to Biogen (BIIB) stock based on the movements in the options market lately.